Scancell, CR UK publish joint vaccine update
SCIB2 is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Read More
Tag: nanoparticle
- Tremfya data show sustained remission in ulcerative colitis through 3 years
- Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
